cgp 12177 has been researched along with Depressive Disorder in 2 studies
CGP 12177 : A benzimidazole that is benzimidazol-2-one substituted at position 4 by a 3-(tert-butylamino)-2-hydroxypropoxy group.
Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harkin, A | 1 |
| Nally, R | 1 |
| Kelly, JP | 1 |
| Leonard, BE | 1 |
| De Paermentier, F | 1 |
| Crompton, MR | 1 |
| Katona, CL | 1 |
| Horton, RW | 1 |
2 other studies available for cgp 12177 and Depressive Disorder
| Article | Year |
|---|---|
Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and beta1-adrenergic receptors in an animal model of depression.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Animals; Cerebral Cortex; Depressive Diso | 2000 |
beta-adrenoceptors in brain and pineal from depressed suicide victims.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents; Binding Sites; Brain; Depressive Disorder; Femal | 1992 |